Our current pipeline aims to disrupt existing treatment paradigms by combining new molecular entities and a leading-edge platform with first-in-class potential for the treatment of autoimmune, inflammatory and other debilitating diseases.
Pipeline
| Program | Indication(s) | Discovery | Preclinical | Phase I | Phase II | Phase III | Next Milestone | ||
|---|---|---|---|---|---|---|---|---|---|
 |
BBI-02 DYRK1A Inhibitor |
|
SAD/MAD Topline Results: Early 2023 |
||||||
 |
BBI-03 DYRK1A Inhibitor |
|
Formulation Development |
||||||
|
BBI-10 STING Inhibitor |
Autoinflammatory & Rare Genetic Diseases |
Preclinical Development |
||||||
|
Next-Generation Kinase Inhibitors DYRK1A, LRRK2, TTK & CLK |
Autoimmune & Neuroinflammation |
Experimental
Characterization |
||||||
 Topical  Oral
|
|||||||||